Better Knowledge for Better Care with QIAGEN and N-of-One: Precision medicine for any cancer assay on any platform
For NGS cancer testing, keeping pace with new discoveries is a serious bottleneck. Valuable information can go undetected due to inadequate mining and interpretation mechanisms. These are called "knowledge blind spots" and can have significant clinical consequences.
QIAGEN is the world leader in aggregating genetic disease knowledge resources. For the past 20 years, we have partnered with clinical testing labs throughout the world to manually curate genetic evidence across all human genes (23,000).
N-of-One’s approach combines expert curation, the insights of oncology experts, and a proprietary technology and knowledgebase, MarkerMine™, to provide curated, high-quality, and actionable clinical interpretation of molecular tests.
Join us for an informative webinar about both clinical interpretation solutions.
For NGS cancer testing, keeping pace with new discoveries is a serious bottleneck. Valuable information can go undetected due to inadequate mining and interpretation mechanisms. These are called "knowledge blind spots" and can have significant clinical consequences.
QIAGEN is the world leader in aggregating genetic disease knowledge resources. For the past 20 years, we have partnered with clinical testing labs throughout the world to manually curate genetic evidence across all human genes (23,000).
N-of-One’s approach combines expert curation, the insights of oncology experts, and a proprietary technology and knowledgebase, MarkerMine™, to provide curated, high-quality, and actionable clinical interpretation of molecular tests.
Join us for an informative webinar about both clinical interpretation solutions.
Hide details